Siemens Healthineers stock heads into Q4 results with 1.8 percent revenue growth

Published on 10/07/2026 at 13:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Siemens Healthineers stock was last at EUR 38.18 on Xetra on October 7, 2026, while Q3 revenue reached EUR 5.764 billion. The Q4 report is scheduled for November 5, 2026.

Bauhaus-Poster mit geometrischen Formen und Text MEDTECH in Primärfarben — Siemens Healthineers DE000SHL1006 gestaltet Bauhaus-Poster mit geometrischen Formen und stilisiertem Scanner-Ring sowie MEDTECH-Schriftzug, Illustration mit AI erstellt.

Siemens Healthineers stock (ISIN DE000SHL1006) was last at EUR 38.18 on Xetra on October 7, 2026 at 1:14 p.m. CEST, up 0.29 percent from the prior close. The next company checkpoint is the fiscal Q4 2026 report scheduled for November 5, 2026.

Q3 profit outpaced revenue

According to VCBeat, revenue for the quarter ended June 30, 2026, reached EUR 5.764 billion, up 1.8 percent from EUR 5.662 billion a year earlier. The same report put adjusted EBIT at EUR 1.101 billion, 15.6 percent above EUR 953 million, and net profit at EUR 676 million, up 21.7 percent from EUR 556 million.

The comparison shows the central investor issue: earnings grew much faster than sales in Q3 fiscal 2026. That gap gives margins greater weight in the next report, particularly as the company enters the final quarter with uneven performance across its businesses.

Guidance reflects Diagnostics pressure

The Q3 update lowered Siemens Healthineers' fiscal 2026 revenue growth guidance to 3.5 percent to 4 percent. According to Quartr, adjusted EPS guidance was raised to EUR 2.35 to EUR 2.45 after tariff refunds lifted both ends of the range by EUR 0.15.

The operating mix remains important for the November release. Quartr's Q3 summary says Precision Therapy grew 9 percent, while Diagnostics weakness prompted the lower top-line outlook and Imaging revenue shifted into the following quarter.

Analyst targets exceed the quote

The analyst table at Simply Wall St lists 19 analysts, an average 12-month target of EUR 45.52, a high of EUR 57.40 and a low of EUR 36.00. The average target lies 19.2 percent above the Xetra price of EUR 38.18.

Finanzen.ch reported on September 30, 2026, that Jefferies maintained a Buy rating and a EUR 50 price target. The target implies a 30.9 percent premium to the October 7 price, leaving the November results as the next test of that view.

Buyback supports the November checkpoint

The Siemens Healthineers investor-relations calendar lists the fiscal Q4 2026 results and analyst call for November 5, 2026, followed by a roadshow on November 6, 2026, according to Siemens Healthineers.

The capital return program is also active. Finanznachrichten reported that 49,987 shares were repurchased from September 28 through October 4, bringing the program total to 3,424,346 shares since June 1, 2026.

Stock remains below yearly high

Siemens Healthineers stock was last at EUR 38.18 on Xetra on October 7, 2026 at 1:14 p.m. CEST, versus a 52-week range of EUR 32.81 to EUR 49.71. Its market capitalization was EUR 42.7 billion and trading volume was 150,425 shares at that timestamp.